Drug intelligence / Profile preview

EXL02

Development stage: Preclinical
Lead developer: Exeliom Biosciences
Modality: Live Biotherapeutic Products → Microbiome Therapeutics

Overview

EXL02 is a preclinical Live Biotherapeutic candidate developed by Exeliom Biosciences. It leverages the properties of specific gut bacteria with a primary focus on activating the Aryl hydrocarbon receptor (AhR) pathway. This drug candidate is part of a pipeline that includes other Live Biotherapeutic Products aimed at modulating immune responses, often in the context of gut microbiome interactions. Its development is in the early stages, with preclinical studies exploring its potential therapeutic applications.

Targets

Ribosome

Beyond the preview

Go deeper on EXL02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXL02.

Explore the full profile